Jeong Mo Bae1,2, Jung Ho Kim1,3, Yoonjin Kwak3,4, Dae-Won Lee5, Yongjun Cha5, Xianyu Wen1, Tae Hun Lee1, Nam-Yun Cho1, Seung-Yong Jeong6, Kyu Joo Park6, Sae Won Han5, Hye Seung Lee3,4, Tae-You Kim5, Gyeong Hoon Kang1,3. 1. Laboratory of Epigenetics, Cancer Research Institute, Seoul National University College of Medicine, Seoul 03080, South Korea. 2. Department of Pathology, SMG-SNU Boramae Medical Center, Seoul 07061, South Korea. 3. Department of Pathology, Seoul National University College of Medicine, Seoul 03080, South Korea. 4. Department of Pathology, Seoul National University Bundang Hospital, Seongnam 13620, South Korea. 5. Department of Internal Medicine, Seoul National University Hospital, 'Seoul 03080, South Korea. 6. Department of Surgery, Seoul National University Hospital, Seoul 03080, South Korea.
Sir,We thank Tapial for their interest in our recent study. The authors applied our revised CIMP classification to their three different clinical data sets, which are composed of patients with early-onset colorectal cancer (EOCRC) (younger than 45 years), patients with late-onset CRC (LOCRC) (older than 70 years), and individuals diagnosed with synchronous CRC (SCRC). They addressed that only LOCRC cases showed similar tendency of increasing BRAF mutation, MSI-high and MLH1 methylation along with the increase in the number of methylated genes. Moreover, they insisted that prognostic results were only partially confirmed in SCRC.Non-linearity of molecular alterations including BRAF mutation, MSI-high and MLH1 methylation in EOCRC and SCRC might originate from two reasons. First, EOCRC and SCRC have strong germline predispositions to CRC, even though they are not either familial adenomatous polyposis or Lynch syndrome (Cybulski ; de Voer ). Recent studies revealed that germline predisposition in EOCRC is greater than expected (Pearlman ); these germline predispositions are mainly associated with chromosomal instability rather than CIMP (Chan ; McGivern ). Second, CIMP-P2 CRCs usually occur in elderly patients. Two recent studies showed similar tendency in CRCs with BRAF mutation and concurrent MSI or MLH1 methylation (Seppala ; Vedeld ).The authors tried to validate prognostic value of our revised CIMP classification in their EOCRC, LOCRC and SCRC subgroups. However, considering their previous publication, the sample size of each subgroup is too small to get enough statistical power for the subgroup of low prevalence, such as CIMP-P1 and CIMP-P2 (Ogino ; Perea ; Arriba ). Considering the low prevalence of EOCRC and SCRC, a multi-centre study might be necessary to validate the prognostic value of our revised CIMP classification.Overall, Tapial et al’s results emphasise the fact that EOCRC and SCRC have different molecular landscapes compared with sporadic CRCs. Further comprehensive study might shed light on the complex interaction between germline predisposition, accumulation of somatic mutation and epigenetic alteration.
Authors: María Arriba; Ricardo Sánchez; Daniel Rueda; Laura Gómez; Juan L García; Yolanda Rodríguez; José Antonio Pajares; Jessica Pérez; Miguel Urioste; Rogelio González Sarmiento; José Perea Journal: Clin Colorectal Cancer Date: 2016-08-09 Impact factor: 4.481
Authors: T L Chan; L C Curtis; S Y Leung; S M Farrington; J W Ho; A S Chan; P W Lam; C W Tse; M G Dunlop; A H Wyllie; S T Yuen Journal: Oncogene Date: 2001-08-09 Impact factor: 9.867
Authors: José Perea; Juana M Cano; Daniel Rueda; Juan L García; Lucía Inglada; Irene Osorio; María Arriba; Jessica Pérez; Miriam Gaspar; Tamara Fernández-Miguel; Yolanda Rodríguez; Javier Benítez; Rogelio González-Sarmiento; Miguel Urioste Journal: Am J Cancer Res Date: 2015-06-15 Impact factor: 6.166
Authors: A McGivern; C V A Wynter; V L J Whitehall; T Kambara; K J Spring; M D Walsh; M A Barker; S Arnold; L A Simms; B A Leggett; J Young; J R Jass Journal: Fam Cancer Date: 2004 Impact factor: 2.375
Authors: Rachel Pearlman; Wendy L Frankel; Benjamin Swanson; Weiqiang Zhao; Ahmet Yilmaz; Kristin Miller; Jason Bacher; Christopher Bigley; Lori Nelsen; Paul J Goodfellow; Richard M Goldberg; Electra Paskett; Peter G Shields; Jo L Freudenheim; Peter P Stanich; Ilene Lattimer; Mark Arnold; Sandya Liyanarachchi; Matthew Kalady; Brandie Heald; Carla Greenwood; Ian Paquette; Marla Prues; David J Draper; Carolyn Lindeman; J Philip Kuebler; Kelly Reynolds; Joanna M Brell; Amy A Shaper; Sameer Mahesh; Nicole Buie; Kisa Weeman; Kristin Shine; Mitchell Haut; Joan Edwards; Shyamal Bastola; Karen Wickham; Karamjit S Khanduja; Rosemary Zacks; Colin C Pritchard; Brian H Shirts; Angela Jacobson; Brian Allen; Albert de la Chapelle; Heather Hampel Journal: JAMA Oncol Date: 2017-04-01 Impact factor: 31.777
Authors: T T Seppälä; J P Böhm; M Friman; L Lahtinen; V M J Väyrynen; T K E Liipo; A P Ristimäki; M V J Kairaluoma; I H Kellokumpu; T H I Kuopio; J-P Mecklin Journal: Br J Cancer Date: 2015-05-14 Impact factor: 7.640
Authors: Richarda M de Voer; Marc-Manuel Hahn; Robbert D A Weren; Arjen R Mensenkamp; Christian Gilissen; Wendy A van Zelst-Stams; Liesbeth Spruijt; C Marleen Kets; Junxiao Zhang; Hanka Venselaar; Lilian Vreede; Nil Schubert; Marloes Tychon; Ronny Derks; Hans K Schackert; Ad Geurts van Kessel; Nicoline Hoogerbrugge; Marjolijn J L Ligtenberg; Roland P Kuiper Journal: PLoS Genet Date: 2016-02-22 Impact factor: 5.917